Search Results
Nov 06, 2025, 14:42 ET Nitinotes riceve l'approvazione del marchio CE per EndoZip™, il primo sistema di sutura completamente automatizzato per la gastroplastica restrittiva endoscopica
milioni di adulti in tutto il mondo. Gli attuali percorsi terapeutici lasciano un divario significativo tra la gestione medica, come la terapia con GLP-1, e la chirurgia bariatrica invasiva. L'ESG si sta affermando come un'alternativa minimamente invasiva, rivolta ai pazienti obesi (BMI 30–40 kg/m²) che
More news about: Nitinotes
Nov 06, 2025, 14:30 ET Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®
cardiovascular disease, with or without type 2 diabetes. Safety data generated in the REDEFINE 1 trial were comparable with the GLP-1 RA class. Overall, discontinuation rates due to adverse events were low, with 6% for CagriSema versus 3.7% for placebo. In REDEFINE 1, adverse events
More news about: NOVO NORDISK INC.
Nov 06, 2025, 14:30 ET Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®
cardiovascular disease, with or without type 2 diabetes. Safety data generated in the REDEFINE 1 trial were comparable with the GLP-1 RA class. Overall, discontinuation rates due to adverse events were low, with 6% for CagriSema versus 3.7% for placebo. In REDEFINE 1, adverse events
More news about: NOVO NORDISK INC.
Nov 06, 2025, 13:54 ET Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans
physical activity. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children. Warnings
More news about: Eli Lilly and Company
Nov 06, 2025, 09:30 ET Nitinotes Receives CE Mark Approval of EndoZip™, the First Fully Automated Suturing System for Endoscopic Sleeve Gastroplasty
than 650 million adults worldwide. Current treatment pathways leave a significant gap between medical management such as GLP-1 therapy and invasive bariatric surgery. ESG is emerging as a minimally invasive alternative, addressing patients with obesity (BMI 30–40 kg/m²)
More news about: Nitinotes
Nov 06, 2025, 09:30 ET Nitinotes Receives CE Mark Approval of EndoZip™, the First Fully Automated Suturing System for Endoscopic Sleeve Gastroplasty
challenges, affecting more than 650 million adults worldwide. Current treatment pathways leave a significant gap between medical management such as GLP-1 therapy and invasive bariatric surgery. ESG is emerging as a minimally invasive alternative, addressing patients with obesity (BMI 30–40 kg/m²) who
More news about: Nitinotes
Nov 06, 2025, 09:00 ET Health Insurance Open Enrollment: Most Americans are Satisfied with Coverage, But 73% Delay Care Due to Costs
Americans: On coverage for GLP-1 drugs 55% of Americans mistakenly believe that GLP-1 drugs are covered for weight loss by most health insurance plans.
More news about: eHealth, Inc.
Nov 06, 2025, 08:31 ET MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update
peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In
More news about: MetaVia Inc.
Nov 06, 2025, 08:30 ET Datassential Releases 2026 Food and Beverage Trends Report
year: Fiber to the Max - Fiber is the New Protein: Fiber (which can naturally increase the GLP-1 hormone in the body) is poised to overtake protein and be the next big health trend, particularly at retail, where new products are popping up highlighting
More news about: Datassential
Nov 06, 2025, 08:00 ET Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity
rats. Encouraging safety and tolerability, with no hERG or Ames assay findings and no toxicity observed in a 28-day non-GLP rat study. "These results position PL7737's potential as a differentiated oral therapy for obesity," said
More news about: Palatin Technologies, Inc.
Nov 06, 2025, 08:00 ET Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025
favorable benefit to risk profile as a non-invasive option for use as an adjunct to GLP-1 receptor agonist chronic weight management therapies and/or as a monotherapy post cessation of GLP-1 receptor agonist chronic weight management therapies with demonstrated benefits to the
More news about: Lipocine Inc.
Nov 06, 2025, 07:22 ET Eilean Therapeutics to Present First-in-Class, Wild-Type-Sparing JAK2-JH2/V617F Inhibitor ZE74-0282 at ASH 2025 and Initiate Clinical Studies in December 2025
compared with fedratinib in xenograft models. Linear pharmacokinetics and toxicokinetics in DRF and GLP toxicology studies, demonstrating safety, tolerability, and a broad therapeutic window supporting optimal clinical dose selection.
More news about: Eilean Therapeutics
Nov 06, 2025, 07:05 ET Viking Therapeutics Highlights Clinical Data from VK2735 Obesity Program in Presentation at ObesityWeek® 2025
or moderate. About GLP-1 and Dual GLP-1/GIP Agonists Activation of the glucagon-like peptide 1 (GLP-1) receptor has been shown to decrease glucose, reduce appetite, lower body
More news about: Viking Therapeutics, Inc.
Nov 05, 2025, 13:08 ET NEWBEAUTY LAUNCHES DIGITAL GLP-1 EDUCATION PLATFORM: STEP BEYOND THE SCALE
was determined that 30 percent of the brand's audience is currently taking GLP-1 medications, and an additional 30 percent is interested in taking them. Additionally, more than two-thirds of GLP-1 users have lost over 20 pounds, which is prompting a new wave of aesthetic goals.Patients
More news about: NewBeauty
Nov 05, 2025, 13:07 ET Nutrishop Raises the Bar with WRKETHIC Grass-Fed Whey Isolate
Created for families, fitness enthusiasts, and today ' s GLP-1 users, new protein powder delivers transparency and real results HENDERSON,
More news about: Nutrishop
Nov 05, 2025, 08:15 ET Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors
review of this NDA is anticipated to be completed by the end of this year.8 Currently, there are no approved oral formulations of a GLP-1 medicine for weight loss. If approved by the FDA, Wegovy® in a pill will be fully made in the US, with production already underway
More news about: NOVO NORDISK INC.
Nov 05, 2025, 08:15 ET Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors
this NDA is anticipated to be completed by the end of this year.8 Currently, there are no approved oral formulations of a GLP-1 medicine for weight loss. If approved by the FDA, Wegovy® in a pill will be fully made in the US, with production already underway
More news about: NOVO NORDISK INC.
Nov 05, 2025, 08:03 ET NextPlat's Healthcare Division Awarded Multi-State Prescription Fulfillment Contract by Virtual Healthcare Provider DevotedDOc
offering an array of services including urgent care and Medication-Assisted Treatment (MAT) for opioid use disorder, as well as compounded alternatives to GLP-1s including semaglutide (Wegovy® and Ozempic®) and tirzepatide (Zepbound® and Mounjaro®) for weight loss and Hormone Replacement therapy (HRT). It currently
More news about: NextPlat Corp.
Nov 04, 2025, 19:10 ET Ascletis Presents Full Analysis of Phase Ib Study of ASC30 Oral Tablet, Phase Ib Study of ASC30 Injection, and Preclinical Study of Combination of ASC31 and ASC47 at ObesityWeek® 2025
The safety profile of ASC30 tablets was consistent with or better than that of the GLP-1R agonist class. Abstract Title: ASC30, a Once-Monthly SQ Injected Small Molecule GLP-1RA in Participants with Obesity: A Ph Ib Study
More news about: Ascletis Pharma Inc.
Nov 04, 2025, 19:10 ET 歌禮在2025年肥胖周（ObesityWeek®）報告ASC30口服片Ib期研究的完整分析、ASC30注射劑Ib期研究以及ASC31與ASC47聯合用藥臨床前研究
）小鼠研究中， ASC47 與 ASC31 （新型 GLP-1R 及 GIPR 雙靶點激動劑多肽）的聯合療法在減重、減脂及不減肌方面均顯著優於替爾泊肽單藥和 ASC31
More news about: 歌禮製藥有限公司
Nov 04, 2025, 16:05 ET Viking Therapeutics to Participate at Upcoming Investor Conferences
therapeutics designed to improve patients' lives. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. The company is
More news about: Viking Therapeutics, Inc.
Nov 04, 2025, 16:01 ET MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025
(OXM) analogue functioning as a GLP1R/GCGR dual agonist for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH) that is to be administered once weekly subcutaneously. DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR),
More news about: MetaVia Inc.
Nov 04, 2025, 16:01 ET AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
MariTide is a differentiated antibody-peptide conjugate that activates the glucagon like peptide 1 (GLP-1) receptor and antagonizes the glucose-dependent insulinotropic polypeptide receptor (GIPR). MARITIME-1, a Phase 3
More news about: Amgen
Nov 04, 2025, 14:00 ET CIR-0602K Demonstrates Synergistic Metabolic Benefit with Tirzepatide: New Data Presented at ObesityWeek 2025
phenotype ("bad fat" to "good fat"), both alone and on top of GLP-1 and GLP-1/GIP agonists. In combination with GLP-1/GIP dual agonist tirzepatide, the synergistic transformation of subcutaneous adipose tissue
More news about: Cirius Therapeutics
Nov 04, 2025, 12:04 ET Currax Announces ObesityWeek® Data Showing that CONTRAVE® Helps Curb Cravings and Offers Marked Effectiveness in Certain Populations with Obesity
ObesityWeek® 2025 press conference on November 5th, were among seven presentations showing the benefits of CONTRAVE, an oral, non-GLP-1 weight loss medication. These presentations are being shared during the annual conference of The Obesity Society, held Nov. 4-7 in Atlanta,
More news about: Currax Pharmaceuticals LLC